This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
April 11, 2019: acute syphilis and virologic control; neuropsychological performance after switching off efavirenz; structural LGBTQ stigma and HIV criminalization in U.S. states; lung cancer resection surgery in people with HIV.
More research is needed to understand the connections between HIV, mental health, and the neurocircuitry that controls executive function.
Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.
HIV-associated neurocognitive disorders, including dementia, may be well-documented issues, but they're still being understood. New research answers some questions providers may have about HIV's impact on the brain.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.
A staggering 60% of patients with HIV experience chronic pain compared with only 11% of the general population, according to Robert Bruce, M.D., M.A., M.Sc., who presented the latest research on pain and HIV at IDWeek 2018.
Efavirenz (Sustiva, Stocrin) use was associated with a 60% increased risk of neurological conditions in children, according to data presented at IDWeek 2018 in San Francisco.